These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39052242)

  • 1. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.
    Birrer M; Li G; Yunokawa M; Lee JY; Kim BG; Oppermann CP; Zhou Q; Nishio S; Okamoto A; Wu X; Mileshkin L; Oaknin A; Ray-Coquard I; Hasegawa K; Jehl G; Vugmeyster Y; Zhang S; Bajars M; Yonemori K
    JAMA Oncol; 2024 Sep; 10(9):1204-1211. PubMed ID: 39052242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
    Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
    Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
    Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
    Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
    Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
    J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
    Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
    Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
    Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
    Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
    Cho BC; Lee JS; Wu YL; Cicin I; Dols MC; Ahn MJ; Cuppens K; Veillon R; Nadal E; Dias JM; Martin C; Reck M; Garon EB; Felip E; Paz-Ares L; Mornex F; Vokes EE; Adjei AA; Robinson C; Sato M; Vugmeyster Y; Machl A; Audhuy F; Chaudhary S; Barlesi F
    J Thorac Oncol; 2023 Dec; 18(12):1731-1742. PubMed ID: 37597750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Yoo C; Javle MM; Verdaguer Mata H; de Braud F; Trojan J; Raoul JL; Kim JW; Ueno M; Lee CK; Hijioka S; Cubillo A; Furuse J; Azad N; Sato M; Vugmeyster Y; Machl A; Bajars M; Bridgewater J; Oh DY; Borad MJ
    Hepatology; 2023 Sep; 78(3):758-770. PubMed ID: 36999533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
    Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
    Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
    Doi T; Fujiwara Y; Koyama T; Ikeda M; Helwig C; Watanabe M; Vugmeyster Y; Kudo M
    Oncologist; 2020 Sep; 25(9):e1292-e1302. PubMed ID: 32324927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
    Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC.
    Lim HY; Heo J; Peguero JA; Ryoo BY; Decaens T; Barlesi F; Moehler MH; Jehl G; Eggleton SP; Bajars M; Gulley JL
    Hepatology; 2025 Jan; 81(1):32-43. PubMed ID: 39141577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
    Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
    Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
    O'Malley DM; Neffa M; Monk BJ; Melkadze T; Huang M; Kryzhanivska A; Bulat I; Meniawy TM; Bagameri A; Wang EW; Doger de Speville Uribe B; Hegg R; Ortuzar Feliu W; Ancukiewicz M; Lugowska I
    J Clin Oncol; 2022 Mar; 40(7):762-771. PubMed ID: 34932394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
    Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
    Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
    Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
    Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of
    Spira A; Awada A; Isambert N; Lorente D; Penel N; Zhang Y; Ojalvo LS; Hicking C; Rolfe PA; Ihling C; Dussault I; Locke G; Borel C
    Front Oncol; 2022; 12():981940. PubMed ID: 36568239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
    Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
    Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.